SRP-1004

RNA / oligonucleotide

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Spinocerebellar Ataxia Type 2

Competitive landscape

Other ATXN2 (ataxin-2) drugs

BIIB105. Compare all 2 ATXN2 (ataxin-2) drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
SRP-1004: this drugPhase 1RNA / oligonucleotideATXN2 (ataxin-2)not yet gradedNo reviewed efficacy summary
BIIB105
Phase 1/2(overall)
RNA / oligonucleotideAtaxin-2 (ATXN2) mRNA, ATXN2 (ataxin-2)not yet gradedFeatured results are safety only

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow SRP-1004 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Spinocerebellar Ataxia Type 2Active not recruiting
Est. primary completion 2026-12 · NCT06672445 · CT.gov ↗
What to watch

See the full readout calendar ↗